Trial Profile
An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs NEO-PV 01 (Primary) ; Nivolumab (Primary) ; Poly ICLC (Primary)
- Indications Bladder cancer; Carcinoma; Malignant melanoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors BioNTech; Neon Therapeutics
- 10 Jun 2020 Status changed from active, no longer recruiting to completed.
- 08 Nov 2019 According to a Neon Therapeutics media release, updated results (n=82, August 2019 data cut) from the trial were presented at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting in National Harbor, MD
- 08 Nov 2019 Results presented in the Neon Therapeutics media release.